EMA Withdrawn: Clopidogrel Teva Pharma B.V. (clopidogrel (as hydrobromide)) — Teva Pharma B.V.

View source ↗

Summary

The EMA withdrew clopidogrel Teva Pharma B.V. (clopidogrel as hydrobromide) from marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• clopidogrel (as hydrobromide) (clopidogrel hydrobromide)

Snippet

Status: Withdrawn. Therapeutic area: Peripheral Vascular Diseases;Acute Coronary Syndrome;Myocardial Infarction;Stroke. MAH: Teva Pharma B.V.. Decision date: 21/10/2014